Our portfolio of on-market IVD assays features the greatest number of companion diagnostics for targeted and immunotherapies, covering many therapies and indications. We also offer an impressive menu of 75+ assays supported in our CAP/CLIA lab, which includes many important emerging biomarkers as well as multiplex panels.

In collaboration with leading pharmaceutical companies, we help to advance precision medicine by innovating and developing high medical value diagnostics that transform the lives of cancer patients. Our standardized, fully-automated and easy-to-use solutions enable reliable results and rapid turnaround time, empowering clinicians with essential information to guide timely, personalized treatment strategies.

Our thorough, end-to-end process enables partners to advance and accelerate clinical and research programs aimed at personalizing care for patients. Wherever your company is in the drug development process, we start with the end in mind, employing our world-class capabilities and expertise to build in robust quality while bridging the gap to patient access at every step along the way.